Equities Analysts Set Expectations for COCP Q1 Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Investment analysts at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Cocrystal Pharma in a research note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share. Zacks Research also issued estimates for Cocrystal Pharma’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.64) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cocrystal Pharma currently has an average rating of “Hold” and a consensus target price of $6.00.

Cocrystal Pharma Trading Down 2.0%

NASDAQ:COCP opened at $1.44 on Thursday. Cocrystal Pharma has a 12 month low of $0.86 and a 12 month high of $2.67. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.07. The firm has a market cap of $19.86 million, a P/E ratio of -1.82 and a beta of 1.18.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01.

Institutional Investors Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. T3 Companies LLC acquired a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. 6.72% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Phillip Md Et Al Frost purchased 50,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost of $0.95 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director directly owned 1,888,551 shares of the company’s stock, valued at approximately $1,794,123.45. This trade represents a 2.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 28.14% of the stock is owned by company insiders.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.